Studies have determined that MACRO-targeted antibodies can help intensify the efficacy of CTL4 antibody treatment, and thus enhance the power of immune checkpoint therapy that helps suppress tumor growth in the breast, colon, and skin. The gene discussed is SLC44A4; the disease is neoplasm.